Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers

Jang Ho Lee, Joo Hee Lee, Kyung-Wook Jo, Jin-Won Huh, Yeon-Mok Oh, Jae Seung Lee

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ABSTRACT

Objectives: Two randomized, controlled studies comparing outcomes in patients treated with direct oral anticoagulants or low-molecular weight heparin for cancer-associated venous thromboembolism (VTE) have previously been performed. However, gynecologic cancers accounted for approximately 10% of the study populations. We compared the outcomes of patients with primary gynecological cancers who were treated for cancer-associated VTE with either rivaroxaban or dalteparin.

Methods: The 162 eligible patients with gynecologic cancers who were treated with either dalteparin (n=60) or rivaroxaban (n=102) were reviewed. The primary outcome was a composite event, which included recurrence or clinically relevant bleeding events during the therapeutic period. Secondary outcomes were recurrence, clinically relevant bleeding events, and mortality.

Results: During the therapeutic period, there were no significant differences between the groups in the proportion of composite events, recurrence, or clinically relevant bleeding. Multivariate analysis using the Cox proportional hazards model also showed no significant difference in the number of composite events and clinically relevant bleeding between the groups. In the rivaroxaban group, 44.0% of patients experienced gastrointestinal bleeding and 24.0% experienced urinary tract bleeding. In the dalteparin group, bleeding was most common in the urinary tract (44.4%) and at the injection site (22.2%).

Conclusion: In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin. Therefore, caution should be taken when prescribing rivaroxaban for gynecologic cancer-associated VTE and bleeding events should be carefully monitored.

Keywords: Dalteparin; Genital Neoplasm; Rivaroxaban; Venous Thromboembolism
INTRODUCTION

Malignancies are an important risk factor for venous thromboembolism (VTE), which includes pulmonary embolism and/or deep vein thrombosis [1,2]. Many patients with gynecologic cancers undergo surgery and chemotherapy, which present an additional risk for VTE [3]. Because VTE is associated with poor prognosis and decreased quality of life, adequate management is essential [4-6]. Although direct oral anticoagulants (DOACs) are used as one of the standard therapies for VTE in the general population, low-molecular weight heparin (LMWH) has become the standard therapy for cancer-associated VTE, following the results of the landmark CLOT trial [7-9]. Although there is no firm evidence supporting the use of DOACs, the convenience of use means that these agents have been increasingly used in cancer patients [8,10].

In 2 randomized controlled studies, which compared edoxaban and rivaroxaban with dalteparin, non-inferior safety and efficacy were seen in patients with cancer-associated VTE, although clinically relevant non-major bleeding events were higher in the edoxaban and rivaroxaban groups [11,12]. However, because patients with gynecologic cancers represented only 10% of the patient population in these studies, it is difficult to apply the non-inferiority data relating to DOACs to gynecologic cancers.

Several studies have reported higher rates of uterine and/or other genital tract bleeding in patients treated with DOACs when compared with other anticoagulants [13-15]. DOACs also cause more clinically relevant bleeding in women than in men during the treatment of acute VTE [16,17]. In addition, mucosal lesions in visceral malignancies are associated with increased bleeding risk [18]. Considering these factors, the use of DOACs should be further evaluated in patients with gynecologic cancers, which are associated with several bleeding risk factors. Among direct factor Xa inhibitors, rivaroxaban is associated with a greater risk of bleeding [19,20].

In this study, we compared the incidence of composite events, including clinically relevant bleeding and recurrence, in patients with primary gynecological cancers who were prescribed either rivaroxaban or dalteparin for the treatment of cancer-associated VTE. In addition, the incidence of bleeding events, recurrence, and all-cause mortality was assessed.

MATERIALS AND METHODS

1. Study design and patients

This study was performed at the Asan Medical Center in Korea and involved a review of the electronic medical records of patients diagnosed with gynecologic malignancy and VTE who were prescribed dalteparin or rivaroxaban therapy. Because there is no standardized protocol for anticoagulant selection, the decision to prescribe rivaroxaban or LMWH is the responsibility of the individual clinician at the study center.

Inclusion criteria were as follows: 1) diagnosis of ovarian, cervical, uterine, vaginal, vulvar, endometrial, or fallopian tube cancer; 2) presence of VTE, as diagnosed via computed tomography or lower extremity Doppler ultrasonography by certificated radiologists; and 3) treatment of VTE with a standard dose of rivaroxaban or dalteparin between January 1, 2012, and December 31, 2017. Exclusion criteria were as follows: 1) anticoagulant therapy initiated at another
institution; 2) rivaroxaban or dalteparin use for ≤7 days without bleeding events; 3) patients lost to follow-up after the first visit; and 4) venous thromboembolic lesions removed by surgery.

The Institutional Review Board of the Asan Medical Center (IRB No. 2017-0652) approved this study. The requirement for informed consent was waived due to the retrospective nature of the analysis.

2. Measurements
Baseline patient characteristics and outcomes were obtained by review of the electronic medical records. The score for bleeding risk factors was calculated as the sum of the number of risk factors, including surgery, in the 2 weeks prior to anticoagulant therapy, concurrent use of antiplatelet agents, presence of a primary or metastatic brain tumor, regionally advanced or metastatic cancer, coexisting gastrointestinal or urothelial cancer, and bevacizumab use in the 6 week period before anticoagulant treatment [11].

The primary outcome in this study was a composite event, which included any one of the following: recurrence, major bleeding, or clinically relevant non-major bleeding events during the therapeutic period. Recurrence of VTE was confirmed by computed tomography or ultrasonographic evidence of an occurrence or increase in pulmonary embolism or deep vein thrombosis at new sites during anticoagulant therapy [11]. Major bleeding was defined as any bleeding event during the therapeutic period that 1) was associated with death; 2) occurred at the fatal site (including intracranial, intraocular, retroperitoneal, intraspinal, or pericardial area); or 3) required a transfusion of at least 2 units of packed red blood cells or led to a decreased hemoglobin level of at least 2.0 g/dL [21]. Any overt bleeding events during the therapeutic period with rivaroxaban or dalteparin that did not meet the criteria for major bleeding but resulted in medical attention, unappointed visits, discontinuation of anticoagulants, or a decrease in daily activities were defined as clinically relevant non-major bleeding [22]. Recurrence, any bleeding events, clinically relevant non-major bleeding, major bleeding, and all-cause mortality were analyzed as secondary outcomes. Recurrence, any bleeding events, clinically relevant non-major bleeding, and major bleeding events were analyzed during therapeutic periods, and all-cause mortality was analyzed until March 31, 2018. Clinically relevant bleeding events included both major bleeding events and clinically relevant non-major bleeding events.

3. Data collection and statistical analysis
Categorical variables are presented as number (%) number and continuous variables as the mean and standard deviation. Differences between the 2 treatment groups were analyzed by the χ² test or Fisher’s exact test and Student’s t-test. Time-to-event curves were calculated by Kaplan-Meier analysis with a log-rank test.

A Cox proportional hazard model was used for univariate and multivariate analysis. Covariates that showed a significant difference between the study groups (p<0.2) were selected. All analyses were performed using SPSS software (version 24.0; IBM, Armonk, NY, USA). The p-values <0.05 were considered as indicative of statistical significance.

RESULTS

1. Study flow and baseline characteristics
Between January 2012 and December 2017, 186 patients with gynecologic cancers were diagnosed with pulmonary embolism and/or deep vein thrombosis. Of these, 24 were
excluded: 11 patients were prescribed rivaroxaban or dalteparin for <7 days, 7 patients were transferred to other hospitals after the first prescription, 5 patients were first prescribed anticoagulants at other hospitals, and one patient underwent surgery to remove a thromboembolic lesion (Fig. 1).

Of the remaining 162 eligible patients, 60 patients were treated with dalteparin and 102 patients received rivaroxaban. The baseline characteristics and bleeding risk factor scores of patients treated in the 2 treatment groups are shown in Table 1. No significant differences in baseline characteristics were seen, with the exception of pulmonary embolism, which was more common in patients receiving dalteparin than in those receiving rivaroxaban (88.3% vs. 47.1%, p<0.001).

2. Study outcomes
During the treatment period, composite events were more common in the rivaroxaban group, but without statistical significance (29.4% in the rivaroxaban group vs. 20.0% in the dalteparin group, p=0.187; Table 2). Although patients in the rivaroxaban group experienced more bleeding events of any type (24.5% vs. 15.0% in the dalteparin group, p=0.151), no statistically significant differences were seen in major bleeding events (7.8% vs. 5.0% in the dalteparin group, p=0.748) or clinically relevant non-major bleeding events (16.7% vs. 10.0% in the dalteparin group, p=0.240). Recurrence, symptomatic recurrence, and all-cause mortality also showed no significant differences between the 2 groups. No patient deaths due to VTE or bleeding were reported. In the dalteparin group, patients with a history of surgery for gynecologic cancer showed an incidence of 7.0% for major bleeding and 18.6% for clinically relevant bleeding. Patients with no history of surgery for gynecologic cancer showed an incidence of 5.9% for clinically relevant bleeding and no major bleeding events.

In the rivaroxaban group, patients with a history of surgery for gynecologic cancer showed an incidence of 6.2% for major bleeding and 24.7% for clinically relevant bleeding. Patients with no history of surgery for gynecologic cancer showed an incidence of 14.3% for major bleeding and 23.8% for clinically relevant bleeding (Supplementary Table 1).

Fig. 2 shows Kaplan-Meier curves of time to composite events among patients treated with either rivaroxaban or dalteparin, compared using the log-rank test. There was no
A significant difference in time to composite events between the 2 groups (p=0.360). Using a Cox proportional hazards models, univariate and multivariate analyses of the incidence and timing of the composite events during the therapeutic period were performed (Table 3). A history of radiotherapy and pulmonary embolism were included as covariates, which showed significant differences between the study groups with p-values <0.2. The hazard ratio (HR) for composite events among patients receiving rivaroxaban vs. patients receiving dalteparin was 1.369 in the univariate analysis (95% confidence interval [CI]=0.697–2.688; p=0.362) and 1.576.

Table 1. Baseline characteristics of the study cohort

| Characteristic                                | Dalteparin (n=60) | Rivaroxaban (n=102) | p-value |
|----------------------------------------------|-------------------|---------------------|---------|
| Age (yr)                                      | 56.27±10.34       | 56.90±12.32         | 0.738   |
| Smoking history*                              | 1 (1.7)           | 3 (2.9)             | >0.999  |
| GFR <50 mL/min/1.73 m*                        | 2 (3.3)           | 2 (2.0)             | 0.627   |
| Platelet count >100,000/µL                    | 5 (8.3)           | 14 (13.7)           | 0.303   |
| Cancer type                                   |                   |                     | 0.216   |
| Cervical                                     | 11 (18.3)         | 33 (32.4)           |         |
| Ovarian (non-clear cell type)                | 24 (40.0)         | 35 (34.3)           |         |
| Ovarian (clear cell type)                    | 10 (16.7)         | 8 (7.8)             |         |
| Uterine                                      | 10 (16.7)         | 12 (11.8)           |         |
| Vaginal                                      | 0 (0.0)           | 1 (1.0)             |         |
| Vulvar                                       | 1 (1.7)           | 1 (1.0)             |         |
| Endometrial                                  | 2 (3.3)           | 10 (9.8)            |         |
| Fallopian                                    | 2 (3.3)           | 2 (2.0)             |         |
| Metastasis                                   | 50 (83.3)         | 79 (77.5)           | 0.369   |
| Coexisting cancer*                            | 2 (3.3)           | 1 (1.0)             | 0.556   |
| Brain lesion*                                 | 2 (3.3)           | 1 (1.0)             | 0.556   |
| Ascites                                      | 27 (45.0)         | 33 (32.4)           | 0.107   |
| History of chemotherapy                      | 46 (76.7)         | 75 (73.5)           | 0.657   |
| Chemotherapy during anticoagulation          | 37 (61.7)         | 55 (53.9)           | 0.377   |
| History of radiotherapy                      | 13 (21.7)         | 32 (31.4)           | 0.183   |
| History of surgery for gynecologic cancer    | 43 (71.7)         | 81 (79.4)           | 0.261   |
| Pulmonary embolism                           | 53 (88.3)         | 48 (47.1)           | <0.001  |
| History of VTE*                               | 1 (1.7)           | 2 (2.0)             | >0.999  |
| Concurrent cerebral infarct*                 | 1 (1.7)           | 6 (5.9)             | >0.999  |
| Recent operation                             | 5 (8.3)           | 11 (10.8)           | 0.614   |
| IVC filter insertion                         | 16 (26.7)         | 30 (29.4)           | 0.708   |
| Antiplatelet agent*                          | 2 (3.3)           | 3 (2.9)             | >0.999  |
| Therapeutic duration (day)                   | 103.32±91.80      | 118.63±179.29       | 0.539   |
| Risk factors for bleeding                    |                   |                     | 0.723   |
| 0                                            | 42 (70.0)         | 72 (70.6)           |         |
| 1                                            | 16 (26.7)         | 24 (23.5)           |         |
| 2–3                                          | 2 (3.3)           | 6 (5.9)             |         |

Values are presented as number (%). Differences between both groups were analyzed by the \( \chi^2 \) test, Fisher’s exact test, or independent 2-sample t-test.

GFR, glomerular filtration rate; IVC, inferior vena cava; VTE, venous thromboembolism.

*Variables analyzed by Fisher’s exact test.

A significant difference in time to composite events between the 2 groups (p=0.360). Using a Cox proportional hazards models, univariate and multivariate analyses of the incidence and timing of the composite events during the therapeutic period were performed (Table 3). A history of radiotherapy and pulmonary embolism were included as covariates, which showed significant differences between the study groups with p-values <0.2. The hazard ratio (HR) for composite events among patients receiving rivaroxaban vs. patients receiving dalteparin was 1.369 in the univariate analysis (95% confidence interval [CI]=0.697–2.688; p=0.362).

Table 2. Primary and secondary endpoints in both groups

| Characteristic                                | Dalteparin (n=60) | Rivaroxaban (n=102) | p-value |
|----------------------------------------------|-------------------|---------------------|---------|
| Composite event                              | 12 (20.0)         | 30 (29.4)           | 0.187   |
| Recurrence*                                  | 4 (6.7)           | 6 (5.9)             | >0.999  |
| Symptomatic recurrence*                      | 1 (1.7)           | 3 (2.9)             | >0.999  |
| Any bleeding                                 | 9 (15.0)          | 25 (24.5)           | 0.151   |
| Major bleeding*                              | 3 (5.0)           | 8 (7.8)             | 0.748   |
| CRNM bleeding                                | 6 (10.0)          | 17 (16.7)           | 0.240   |
| All-cause mortality                          | 39 (65.0)         | 71 (69.6)           | 0.544   |

Values are presented as number (%). Differences between both groups were analyzed by the \( \chi^2 \) test or Fisher’s exact test.

CRNM, clinically relevant non-major.

*Variables analyzed by Fisher’s exact test.
in the multivariate analysis (95% CI=0.752–3.305; p=0.229). Covariates, including a history of radiotherapy and accompanying pulmonary embolism, also showed no significant differences.

Table 4 shows the HRs for the clinically relevant bleeding events using a Cox proportional hazards model. In this analysis, rivaroxaban was associated with an increased HR of clinically relevant bleeding vs. dalteparin in univariate (HR=1.450; 95% CI=0.673–3.126; p=0.343) and multivariate analysis (HR=1.445; 95% CI=0.614–3.398; p=0.399). However, there was no statistically significant difference between the groups.

Table 5 shows the sites of bleeding events. Nine patients receiving dalteparin presented with clinically relevant bleeding events; of these, the urinary tract (44.4%) was the most common, followed by the injection site (22.2%). Among patients receiving rivaroxaban, 25 patients developed clinically relevant bleeding events; the gastrointestinal tract was the most common bleeding site (44.0%), followed by the urinary tract (24.0%).

---

**Table 3.** HR for the composite event in the Cox proportional hazards model

| Covariate          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | HR (95% CI)         | p-value               | HR (95% CI)         | p-value               |
| Anticoagulants     |                     |                       |                      |                       |
| Dalteparin         | 1                   |                       | 1                    |                       |
| Rivaroxaban        | 1.369 (0.697–2.688) | 0.362                 | 1.576 (0.752–3.305) | 0.229                 |
| History of RTx     | 1.168 (0.595–2.294) | 0.652                 | 1.197 (0.603–2.374) | 0.608                 |
| Pulmonary embolism | 1.112 (0.593–2.084) | 0.742                 | 1.388 (0.690–2.790) | 0.358                 |

CI, confidence interval; HR, hazard ratio; RTx, radiotherapy.

**Table 4.** HRs for clinically relevant bleeding events using the Cox proportional hazards model

| Covariate          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | HR (95% CI)         | p-value               | HR (95% CI)         | p-value               |
| Anticoagulants     |                     |                       |                      |                       |
| Dalteparin         | 1                   |                       | 1                    |                       |
| Rivaroxaban        | 1.450 (0.673–3.126) | 0.343                 | 1.445 (0.614–3.398) | 0.399                 |
| History of RTx     | 0.877 (0.395–1.947) | 0.748                 | 0.848 (0.380–1.893) | 0.688                 |
| Pulmonary embolism | 0.844 (0.425–1.676) | 0.628                 | 0.969 (0.450–2.088) | 0.936                 |

CI, confidence interval; HR, hazard ratio; RTx, radiotherapy.
DISCUSSION

Two randomized controlled studies comparing the outcome of DOACs and LMWH treatment for cancer-associated VTE have previously been performed [11,12]. Following these studies, several guidelines were published recommending that DOACs could be considered as an alternative to LMWH for the treatment of cancer-associated VTE [8,10]. However, patients with a variety of cancer types were included in these studies and additional studies are required to evaluate the efficacy and safety of DOACs for VTE in each cancer type. As the urinary tract is commonly invaded by gynecologic cancer and one of the most important bleeding risk factors associated with DOACs in cancer patients is visceral lesions in the urinary or gastrointestinal tracts, it is important to determine the safety of DOACs in patients with gynecologic cancer [18].

To our knowledge, only one pilot analysis has compared the risk of rivaroxaban and enoxaparin for the treatment of VTE in gynecologic cancers [23]. Although there was no significant difference in effectiveness or safety between the 2 drugs, the authors urged caution when drawing any conclusions due to the small sample size, which included 18 patients in the rivaroxaban group and 26 in the enoxaparin group. In the current study, we compared rivaroxaban and dalteparin in a larger number of patients with gynecologic cancers.

In the current study, the dalteparin group included more patients with accompanying pulmonary embolism than the rivaroxaban group. However, other baseline characteristics did not differ. A history of radiotherapy and accompanying pulmonary embolism were selected as covariates for the multivariate analysis; although rivaroxaban presented a 1.576 (95% CI=0.752–3.305)-fold increase in risk for the composite event when compared with dalteparin, this difference did not reach statistical significance.

There are 2 previous studies of rivaroxaban for the treatment of patients with gynecologic cancers and VTE [23,24]. Although the current study included a larger number of patients than these, we found no significant differences in bleeding incidence and recurrence rates between rivaroxaban and dalteparin, which is standard therapy for cancer-associated VTE. These data indicate that rivaroxaban can be regarded as a reasonable option for the treatment of cancer-associated VTE in patients with gynecologic cancers.

In other previous studies, concern has been raised that rivaroxaban is associated with an increased risk of bleeding in comparison with other DOACs therapies [19,20]. In the current study, clinically relevant bleeding occurred in 24.5% of patients receiving rivaroxaban and
15.0% of patients receiving dalteparin. However, after adjustment, rivaroxaban was not associated with an increased HR for clinically relevant bleeding. Although other DOACs were not included in this study, these results suggested that other DOACs, which have less bleeding tendency than rivaroxaban, may also be used for cancer-associated VTE.

Concern has also been raised that DOACs may increase gastrointestinal bleeding compared with other anticoagulants [25-27]. While the exact mechanism for increased gastrointestinal bleeding is not fully understood, several hypotheses have been proposed. DOACs are actively secreted into the gastrointestinal tract via the P-glycoprotein transport system [28]. Part of the DOACs have low bioavailability, and secreted and unabsorbed DOAC compounds are activated in the gastrointestinal tract [29]. Continued exposure of the gastrointestinal tract to active DOAC compounds can increase the risk of gastrointestinal tract bleeding. In the current study, among the 25 patients with bleeding in the rivaroxaban group, 11 (44.0%) presented with gastrointestinal bleeding. By contrast, there were no patients with gastrointestinal bleeding in the dalteparin group. These findings are similar to those of previous studies of rivaroxaban [25,29,30], and suggest that clinicians should consider other gastrointestinal bleeding risk factors before prescribing rivaroxaban, such as concomitant use of ulcerogenic agents, patient age, the presence of renal impairment or peptic ulcers, or high hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly (HAS-BLED) scores [31].

There are several limitations to the current study. First, the retrospective design may have introduced selection bias, although the similarity in baseline characteristics between the 2 groups may reduce this risk. Secondly, most clinicians did not prescribe imaging studies for the evaluation of VTE recurrence and information regarding clinically relevant bleeding events was collected through electronic medical records. Therefore, it is possible that asymptomatic recurrences or clinically relevant non-major bleeding events were underestimated. Finally, this study included a relatively small number of patients. Therefore, a large, randomized, controlled study would be required to confirm the effectiveness and safety of rivaroxaban for the treatment of VTE in patients with primary gynecologic cancers.

In conclusion, no significant differences in effectiveness or safety were seen between patients with gynecologic cancers receiving rivaroxaban or dalteparin for the treatment of cancer-associated VTE. Rivaroxaban may, therefore, be regarded as a suitable treatment option for VTE associated with gynecologic cancers. However, as rivaroxaban treatment was associated with a higher incidence of the composite event and clinically relevant bleeding, clinicians should be cautious when prescribing rivaroxaban for cancer-associated VTE in gynecologic cancers and bleeding events and recurrence should be carefully monitored. Further prospective studies in larger patient groups will be required to clearly evaluate the safety and effectiveness of DOACs and LMWH for the treatment of VTE in patients with gynecologic cancers.

**SUPPLEMENTARY MATERIAL**

**Supplementary Table 1**
Frequency of bleeding events occurring in the dalteparin and rivaroxaban groups according to history of surgery for gynecologic cancer

Click here to view
REFERENCES

1. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-74.
   PUBMED | CROSSREF

2. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712-23.
   PUBMED | CROSSREF

3. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 2013;18:1321-9.
   PUBMED | CROSSREF

4. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010;363:266-74.
   PUBMED | CROSSREF

5. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
   PUBMED | CROSSREF

6. Franchini M, Bonfanti C, Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res 2015;135:777-81.
   PUBMED | CROSSREF

7. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounnameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52.
   PUBMED | CROSSREF

8. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw 2018;16:1289-303.
   PUBMED | CROSSREF

9. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
   PUBMED | CROSSREF

10. Khorana AA, Noble S, Lee AY, Soff G, Meyer G, O’Connell C, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1891-4.
   PUBMED | CROSSREF

11. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2016;378:615-24.
   PUBMED | CROSSREF

12. Young AM, Marshall A, Thrivwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low-molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-23.
   PUBMED | CROSSREF

13. Boonyawat K, O’Brien SH, Bates SM. How I treat heavy menstrual bleeding associated with anticoagulants. Blood 2017;130:2603-9.
   PUBMED | CROSSREF

14. Cohen H, Arachchilage DR, Beyer-Westendorf J, Middeldorp S, Kadir RA. Direct oral anticoagulants and women. Semin Thromb Hemost 2016;42:789-97.
   PUBMED | CROSSREF

15. Ferreira M, Barsam S, Patel JP, Czuprynska J, Roberts LN, Patel RK, et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016;173:314-5.
   PUBMED | CROSSREF

16. De Crem N, Peerlinck K, Vanassche T, Vanheule K, Dehayeve B, Middeldorp S, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 2015;136:749-53.
   PUBMED | CROSSREF

17. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials. Int J Cardiol 2016;212:255-8.
   PUBMED | CROSSREF

18. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014;19:82-93.
   PUBMED | CROSSREF
19. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:2221-30.

20. Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 2015;10:e0144856.

21. EINSTEIN Investigators Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.

22. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.

23. Signorelli JR, Gandhi AS. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study. J Oncol Pharm Pract 2017;1078155217739683.

24. Renni MJ, Araujo ML Jr, Trugilho I, Bergmann A, de Morais Coura CP. Rivaroxaban used in the treatment patients with gynecologic cancer and venous thromboembolism: the experience of Instituto Nacional de Câncer-Rio de Janeiro, Brazil. Int J Gynecol Cancer 2017;27:1042-5.

25. Imberti D, Cimminiello C, Di Nisio M, Marietta M, Polo Friz H, Ageno W. Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opin Pharmacother 2018;19:1177-85.

26. Brodie MM, Newman JC, Smith T, Rockey DC. Severity of gastrointestinal bleeding in patients treated with direct-acting oral anticoagulants. Am J Med 2018;131:573.e9-573.e15.

27. Desai J, Kolb JM, Weitz JJ, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013;110:205-12.

28. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52:69-82.

29. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol 2015;66:2271-81.

30. Chan NC, Eikelboom JW, Weitz JJ. Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ Res 2016;118:1409-24.

31. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol 2017;23:1954-63.